NRX Pharmaceuticals (NRXP) Total Current Liabilities (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported Total Current Liabilities for 10 consecutive years, with $33.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 16.26% year-over-year to $33.9 million in Q2 2026; TTM through Jun 2026 was $33.9 million, a 16.26% decrease from a year earlier, with the FY2025 full-year figure at $28.6 million, up 30.71% from the prior year.
• Total Current Liabilities was $33.9 million for Q2 2026 at NRX Pharmaceuticals, up from $25.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $40.6 million in Q3 2025 and troughed at $15.6 million in Q4 2022.
• A 5-year average of $26.3 million and a median of $22.6 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 99.98% in 2025 and dropped 23.13% in 2026, its largest moves.
• Over 5 years, Total Current Liabilities stood at $15.6 million in 2022, then gained by 22.22% to $19.0 million in 2023, then climbed by 14.78% to $21.9 million in 2024, then jumped by 30.71% to $28.6 million in 2025, then gained by 18.53% to $33.9 million in 2026.
• The last three Total Current Liabilities figures came in at $33.9 million (Q2 2026), $25.2 million (Q1 2026), and $28.6 million (Q4 2025), per Business Quant data.